Silence Therapeutics plc (SLN) had recently reported positive results from its phase 2 ALPACAR-360 study using its drug zerlasiran [SLN360] for the treatment of patients who are at risk of ...

Individuals who achieved a BMI of less than 25 kg/m2 in the SURMOUNT trials of tirzepatide also experienced significant ...

An AHA scientific statement examines the link between periodontal disease and ASCVD, highlighting shared risk factors and inflammatory mechanisms.

Please provide your email address to receive an email when new articles are posted on . Cardiology health care professionals expressed hesitancy in prescribing FDA-approved obesity medications to ...

Verve Therapeutics, Inc. (VERV) has been making great progress in being able to advance its pipeline, that's because it has done well to advance its main clinical candidate in the pipeline known as ...

Patients with depression were diagnosed with atherosclerotic cardiovascular disease (ASCVD) earlier than those without depression and were more likely to be prescribed lipid-lowering therapy (LLT).

Findings showed treatment with inclisiran led to clinically meaningful and statistically significant LDL-C lowering compared with placebo and ezetimibe. Topline results were announced from the phase 3 ...

Lipoprotein(a) appears to be an egalitarian risk factor, with high levels tied to an increased risk of atherosclerotic cardiovascular disease (ASCVD) in a wide range of primary-prevention patients, ...

The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...

In patients with ASCVD who receive dialysis, statins decrease risk for MACE and all-cause mortality. Statins are associated with a decrease in all-cause mortality and major adverse cardiovascular ...